Kraig Biocraft Laboratories Announces New Spider Silk Parental Strain for Expanded Commercial Production
Kraig Biocraft Laboratories (OTCQB: KBLB) has successfully developed a new recombinant spider silk parental line for large-scale commercial production. This marks the company's third commercial production line, designed to expand output capacity and meet growing material demand. The new strain is part of Kraig's transition to a double hybrid production system, which is expected to deliver improved performance through higher silk yields, increased colony resilience, and reduced production costs.
The development aligns with the company's 2024 production roadmap and represents a strategic step toward scaling from pilot operations to full-scale manufacturing. Several additional parental lines are currently in advanced development stages, supporting Kraig's broader initiative to enhance production scalability, efficiency, and product consistency.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha sviluppato con successo una nuova linea parentale di seta di ragno ricombinante per la produzione commerciale su larga scala. Questa rappresenta la terza linea produttiva commerciale dell'azienda, progettata per aumentare la capacità produttiva e soddisfare la crescente domanda di materiale. Il nuovo ceppo fa parte della transizione di Kraig verso un sistema di produzione ibrido doppio, che promette prestazioni migliorate grazie a rese di seta più elevate, maggiore resilienza delle colonie e costi di produzione ridotti.
Lo sviluppo è in linea con la roadmap produttiva dell'azienda per il 2024 e costituisce un passo strategico verso la scalabilità, passando dalle operazioni pilota a una produzione su larga scala. Diverse altre linee parentali sono attualmente in fase avanzata di sviluppo, a supporto dell'iniziativa più ampia di Kraig per migliorare la scalabilità, l'efficienza produttiva e la coerenza del prodotto.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha desarrollado con éxito una nueva línea parental de seda de araña recombinante para producción comercial a gran escala. Esta es la tercera línea de producción comercial de la empresa, diseñada para ampliar la capacidad de producción y satisfacer la creciente demanda de material. La nueva cepa forma parte de la transición de Kraig hacia un sistema de producción híbrido doble, que se espera ofrezca un mejor rendimiento mediante mayores rendimientos de seda, mayor resiliencia de las colonias y reducción de costos de producción.
Este desarrollo está alineado con la hoja de ruta de producción de la empresa para 2024 y representa un paso estratégico hacia la ampliación desde operaciones piloto a fabricación a gran escala. Varias líneas parentales adicionales se encuentran actualmente en etapas avanzadas de desarrollo, apoyando la iniciativa más amplia de Kraig para mejorar la escalabilidad, eficiencia y consistencia del producto.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 대규모 상업 생산을 위한 새로운 재조합 거미줄 부모 계통을 성공적으로 개발했습니다. 이는 회사의 세 번째 상업 생산 라인으로, 생산 능력을 확장하고 증가하는 소재 수요를 충족시키기 위해 설계되었습니다. 새로운 계통은 Kraig의 이중 하이브리드 생산 시스템 전환의 일부로, 더 높은 실크 수확량, 강화된 군집 회복력, 생산 비용 절감을 통해 성능 향상을 기대하고 있습니다.
이번 개발은 회사의 2024년 생산 로드맵과 일치하며, 파일럿 운영에서 전면 제조로 확장하는 전략적 단계입니다. 여러 추가 부모 계통이 현재 고급 개발 단계에 있으며, Kraig의 생산 확장성, 효율성 및 제품 일관성 향상을 위한 광범위한 이니셔티브를 지원합니다.
Kraig Biocraft Laboratories (OTCQB : KBLB) a développé avec succès une nouvelle lignée parentale de soie d’araignée recombinante pour une production commerciale à grande échelle. Il s’agit de la troisième ligne de production commerciale de l’entreprise, conçue pour augmenter la capacité de production et répondre à la demande croissante en matériaux. Cette nouvelle souche fait partie de la transition de Kraig vers un système de production hybride double, qui devrait offrir de meilleures performances grâce à des rendements de soie plus élevés, une résilience accrue des colonies et une réduction des coûts de production.
Ce développement s’inscrit dans la feuille de route de production de l’entreprise pour 2024 et constitue une étape stratégique vers le passage des opérations pilotes à la fabrication à grande échelle. Plusieurs autres lignées parentales sont actuellement en phase avancée de développement, soutenant l’initiative plus large de Kraig visant à améliorer l’évolutivité, l’efficacité et la cohérence des produits.
Kraig Biocraft Laboratories (OTCQB: KBLB) hat erfolgreich eine neue rekombinante Spinnenseiden-Elternlinie für die großflächige kommerzielle Produktion entwickelt. Dies ist die dritte kommerzielle Produktionslinie des Unternehmens, die darauf ausgelegt ist, die Produktionskapazität zu erweitern und die steigende Materialnachfrage zu erfüllen. Die neue Linie ist Teil von Kraigs Umstellung auf ein doppeltes Hybrid-Produktionssystem, das durch höhere Seidenausbeuten, erhöhte Kolonienresilienz und reduzierte Produktionskosten eine verbesserte Leistung liefern soll.
Die Entwicklung entspricht dem Produktionsfahrplan des Unternehmens für 2024 und stellt einen strategischen Schritt dar, um von Pilotbetrieben zur Vollproduktion zu skalieren. Mehrere weitere Elternlinien befinden sich derzeit in fortgeschrittenen Entwicklungsstadien und unterstützen Kraigs umfassendere Initiative zur Verbesserung der Skalierbarkeit, Effizienz und Produktkonsistenz der Produktion.
- Development of new spider silk parental line increases production capacity
- Double hybrid production system expected to improve silk yields and colony resilience
- Anticipated reduction in overall production costs
- Multiple additional parental lines in advanced development stages
- Still in transition from pilot operations to full-scale manufacturing
- Actual performance improvements and cost reductions yet to be demonstrated
Company Expands Capacity to Meet Material Demand and Scale Inventory by developing new parental Strain for Production
ANN ARBOR, Mich., May 28, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces today the successful development of a new recombinant spider silk parental line, purpose-built for large-scale commercial production.
This newly developed strain represents the third commercial production line created by Kraig Labs as it executes on its strategy to expand output capacity. The addition of this next-generation silk-producing line comes as the Company ramps up production to fulfill current material requests and strategically build inventory for future sales.
"Our team continues to deliver on key milestones as we scale the commercialization of spider silk," said Company Founder and CEO, Kim Thompson. "With the development of this new production strain, we are not only increasing our ability to meet existing demand, but also reinforcing the foundation for our future growth. This new strain is part of the production roadmap we outlined in 2024 and a key part of our transition to a full double hybrid production system."
This latest strain is part of Kraig Labs' broader development pipeline, which includes several additional parental lines currently in advanced stages of development. These lines are designed to enable a transition to a double hybrid production model—expected to deliver significant performance improvements, including higher silk yields, increased colony resilience, and reduced overall production costs.
"As we prepare to implement double hybrid crosses into our production platform, we are opening the door to greater scalability, efficiency, and product consistency," Thompson continued. "This is a key step forward in our mission to bring the power of spider silk to mainstream markets."
The Company is continuing its focus on building a robust and scalable production system as it transitions from pilot operations to full-scale manufacturing.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward-looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the significance of KBLB's new spider silk parental strain?
How will the double hybrid production system benefit Kraig Biocraft (KBLB)?
What is Kraig Biocraft's (KBLB) current production status in 2025?
What are the main objectives of KBLB's new spider silk strain development?
